In 2010, all 53 countries* in the World Health Organization (WHO) European Region (EUR) reconfirmed their commitment to eliminating measles and rubella and congenital rubella syndrome (1) ; this goal was included as a priority in the European Vaccine Action Plan 2015-2020 (2) . The WHO-recommended elimination strategies in EUR include 1) achieving and maintaining ≥95% coverage with 2 doses of measles-containing vaccine (MCV) through routine immunization services; 2) providing measles and rubella vaccination opportunities, including supplementary immunization activities (SIAs), to populations susceptible to measles or rubella; 3) strengthening surveillance by conducting case investigations and confirming suspected cases and outbreaks with laboratory results; and 4) improving the availability and use of evidence for the benefits and risks associated with vaccination (3) . This report updates a previous report (4) and describes progress toward measles elimination in EUR during [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] [2017] [2018] . During 2009-2017, estimated regional coverage with the first MCV dose (MCV1) was 93%-95%, and coverage with the second dose (MCV2) increased from 73% to 90%. In 2017, 30 (57%) countries achieved ≥95% MCV1 coverage, and 15 (28%) achieved ≥95% coverage with both doses. During 2009-2018, >16 million persons were vaccinated during SIAs in 13 (24%) countries. Measles incidence declined to 5.8 per 1 million population in 2016, but increased to 89.5 in 2018, because of large outbreaks in several EUR countries. To achieve measles elimination in EUR, measures are needed to strengthen immunization programs by ensuring ≥95% 2-dose MCV coverage in every district of each country, offering supplemental measles vaccination to susceptible adults, maintaining highquality surveillance for rapid case detection and confirmation, and ensuring effective outbreak preparedness and response.
Immunization Activities
Since 2002, all 53 countries in EUR have included 2 MCV doses in routine childhood vaccination schedules. WHO and the United Nations Children's Fund (UNICEF) estimate vaccination coverage for all countries in the region using annual, government-reported administrative coverage data (calculated as the number of doses administered divided by the estimated target population) and vaccination coverage surveys (5) . During 2009-2017, annual estimates of MCV1 coverage were available for all 53 countries, and the number of countries with annual MCV2 coverage estimates increased from 47 (89%) to 52 (98%). During 2009-2017, regional coverage estimates for MCV1 and MCV2 ranged from 93% to 95% and 73% to 90%, respectively ( Figure) . In 2017, 30 (57%) countries achieved ≥95% MCV1 coverage, and 15 (28%) had ≥95% estimated coverage with both doses (Table 1) confirmation and genotyping of measles virus isolates from patients with reported cases (7). Key measles case-based surveillance performance indicators include 1) the number of suspected cases discarded as nonmeasles or nonrubella (target: ≥2 per 100,000 population); 2) the percentage of case investigations conducted within 48 hours of report (target: ≥80%); 3) the percentage of suspected cases (excluding those that are epidemiologically linked) with an adequate specimen collected within 28 days of rash onset and tested in a WHO-accredited or proficient laboratory (target: ≥80%); and 4) the percentage of cases for which the origin of infection (i.e., the source of the virus) is determined (target: ≥80%). During 2009-2018, the number of EUR countries that met the target for suspected cases discarded as nonmeasles at the national level increased from one (3%) in 2009 to 10 (21%) in 2018 (Table 2) . From 2009 to 2018, the number of countries achieving the targets for timely investigations of suspected cases and adequate specimen collection increased from one (3%) to 24 (51%) and from 13 (36%) to 38 (81%), respectively.
Measles Incidence and Genotypes
During 2009-2018, annual regional measles incidence varied from 8.8 per 1 million population (7, 884 
Regional Verification of Measles Elimination
The European Regional Verification Commission for Measles and Rubella Elimination was established in 2011 to evaluate the status of measles and rubella elimination ¶ in EUR countries based on documentation submitted annually by national verification committees (1) . By the end of 2017, ¶ Elimination defined as interruption of endemic measles transmission for >36 months in the presence of a well-functioning surveillance system. 43 (91%) countries had interrupted endemic measles virus transmission for ≥12 months, including 37 (70%)** that had sustained interruption for ≥36 months and were verified to have eliminated endemic measles virus transmission (8) .
Discussion
After relatively stable albeit high measles incidence in EUR during 2009-2016, the number of reported measles cases tripled from 2017 to 2018, including outbreaks in eight countries reporting >2,000 measles cases each. The 2018 measles resurgence was attributable to measles virus transmission that ** Countries that had interrupted endemic measles virus transmission for >12 months include Albania, Andorra, Armenia, Azerbaijan, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Greece, Estonia, Finland, Hungary, Iceland, Ireland, Israel, Latvia, Lithuania, Luxembourg, Malta, Montenegro, Netherlands, North Macedonia, Norway, Monaco, Portugal, Republic of Moldova, San Marino, Slovakia, Slovenia, Spain, Sweden, Tajikistan, Turkmenistan, United Kingdom, and Uzbekistan.
began in 2017 and continued during 2018 in France, Greece, Romania, Russia, Serbia, and Ukraine. In addition, measles virus importations followed by widespread measles virus transmission occurred in countries that had achieved elimination, including Albania, Belarus, Czech Republic, Israel, and Montenegro. Despite high reported national coverage, factors associated with the resurgence included persistent measles virus reservoirs in EUR countries with limited resources and weak immunization systems, an accumulation of susceptible young children in marginalized communities with suboptimal coverage, and an accumulation of susceptible young adults who had escaped both natural measles infection and measles vaccination over a prolonged period of decreased measles incidence. Outbreak response differed among countries. In some countries, large outbreaks caused substantial financial and human resource burdens, which resulted in delayed or inadequate outbreak responses and ongoing disease transmission. In other countries, outbreak response vaccination campaigns were not implemented because of insufficient political commitment, poor acceptance of mass immunization by health authorities and the public, lack of infrastructure to vaccinate specific susceptible population groups, and vaccine supply challenges. To achieve better outbreak control, countries in the region will need to adhere to their commitment to eliminate measles and rubella and ensure that dedicated financial and human resources are available for strong vaccination and surveillance programs, including outbreak preparedness and response.
The measles resurgence and the European Vaccine Action Plan midterm review in 2018 (9) highlighted ongoing challenges, including inadequate vaccine delivery infrastructure in some middle-income countries that resulted in suboptimal vaccination coverage and vaccine stock-outs; prevalent antivaccine sentiment; large populations of unvaccinated persons, including ethnic and religious minorities and adults; an increased proportion of cases in persons aged ≥20 years, who are difficult to reach with routine immunization services; and nosocomial outbreaks that affected patients and health care personnel with spread to the community. All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Summary
What is already known about this topic?
Many countries in the World Health Organization European Region (EUR) have made substantial progress toward measles elimination.
What is added by this report?
By end of 2017, 37 (70%) EUR countries had sustained interruption of measles transmission for ≥36 months and were verified to have eliminated endemic measles. During 2017-2018, however, a resurgence of measles occurred in EUR, with large-scale outbreaks in Ukraine, Serbia, and some countries that had achieved elimination.
What are the implications for public health practice? To achieve regional measles elimination, measures are needed to strengthen immunization programs to achieve high population immunity, maintain high-quality surveillance for rapid case detection, and ensure outbreak preparedness and prompt response to contain outbreaks.
